There's a saying that you'll hear used with perennially successful
sports franchises – they don't rebuild, they reload. That could apply to
Swiss drug giant Roche (OTC:RHHBY)
as well, as the company appears to be well on its way with a second
generation of top-end oncology drugs, supplemented with promising new
drugs in CNS, metabolic disease, and other high-potential treatment
areas. While Roche has questions to answer in its diagnostics and life
science businesses, as well as its capital priorities, the business
looks to be on solid footing for years to come.
Please click the link to read more:
http://www.investopedia.com/stock-analysis/052113/roche-reloaded-rhhby-bmy-gild-mrk-jnj.aspx
No comments:
Post a Comment